CHICAGO TRUST Co NA lessened its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 16.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,625 shares of the biopharmaceutical company’s stock after selling 3,387 shares during the quarter. CHICAGO TRUST Co NA’s holdings in Bristol-Myers Squibb were worth $894,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Bristol-Myers Squibb by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 134,058,636 shares of the biopharmaceutical company’s stock valued at $6,079,559,000 after purchasing an additional 1,580,750 shares during the last quarter. BlackRock Inc. raised its position in Bristol-Myers Squibb by 6.7% in the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after purchasing an additional 7,178,698 shares during the last quarter. FMR LLC raised its position in Bristol-Myers Squibb by 313.9% in the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock valued at $1,949,043,000 after purchasing an additional 30,981,844 shares during the last quarter. Invesco Ltd. raised its position in Bristol-Myers Squibb by 40.4% in the 2nd quarter. Invesco Ltd. now owns 24,012,686 shares of the biopharmaceutical company’s stock valued at $1,088,974,000 after purchasing an additional 6,915,526 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Bristol-Myers Squibb by 67.6% in the 2nd quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock valued at $938,682,000 after purchasing an additional 8,347,432 shares during the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini acquired 11,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were acquired at an average cost of $44.72 per share, for a total transaction of $491,920.00. Following the transaction, the director now directly owns 11,397 shares of the company’s stock, valued at $509,673.84. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by insiders.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the previous year, the firm earned $1.01 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, analysts forecast that Bristol-Myers Squibb Co will post 4.29 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a $0.41 dividend. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.23%. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.
Several research firms recently commented on BMY. Bank of America upped their price target on shares of Bristol-Myers Squibb from $46.00 to $49.00 and gave the company a “neutral” rating in a research report on Tuesday, September 3rd. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target for the company in a research report on Wednesday, August 14th. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a research report on Thursday, June 13th. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, September 13th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $55.74.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Quantitative Easing
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.